Expression of Nuclear Beta-catenin and C-myc is Correlated with Tumor Size but Not with Proliferative Activity of Colorectal Adenomas

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2000 Mar 7

PMID 10702403

Citations 50

Authors

T Brabletz

K Herrmann

A Jung

G Faller

T Kirchner

Affiliations

Soon will be listed here.

Abstract

Most colorectal cancers have loss-of-function mutations in the adenomatosis polyposis coli (APC) tumor suppressor gene. This leads to the accumulation of nuclear beta-catenin, which, together with the DNA-binding protein TCF-4, functions as a transcriptional activator. The recently defined target genes c-myc, cyclin D1, and matrilysin are responsible for tumor proliferation or malignant progression and explain the oncogenic potential of nuclear beta-catenin. To investigate its role in early colon carcinogenesis, we analyzed the expression of beta-catenin, its target gene c-myc, and the proliferative activity in 88 colorectal adenomas of varying size and grade of dysplasia. The results revealed i) the most significant correlation of nuclear beta-catenin and c-myc expression was not with the grade of dysplasia but with the size of the colon adenoma; ii) perfect correlation of nuclear beta-catenin and c-myc expression; iii) no significant correlation of adenoma size with the proliferative activity; and iv) no significant correlation of proliferative activity and the nuclear expression of beta-catenin and c-myc. These results imply that APC mutations have additional beta-catenin-independent functions; APC mutations alone are not sufficient for nuclear overexpression of beta-catenin; and nuclear beta-catenin has additional important functions for exceeding a threshold tumor size.

Citing Articles

miR-575/RIPK4 axis modulates cell cycle progression and proliferation by inactivating the Wnt/β-catenin signaling pathway through inhibiting RUNX1 in colon cancer.

Wang Q, Lu W, Lu L, Wu R, Wu D Mol Cell Biochem. 2024; 479(7):1747-1766.

PMID: 38480605 DOI: 10.1007/s11010-024-04938-w.

Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/-Catenin Complex and Associated Genetic Alterations.

Estopinal M, Middleton L, Esmaeli B, Patel K, Nowroozizadeh S, Williams M Case Rep Pathol. 2021; 2021:6628150.

PMID: 34804623 PMC: 8601830. DOI: 10.1155/2021/6628150.

SPOCK1: a multi-domain proteoglycan at the crossroads of extracellular matrix remodeling and cancer development.

Ye Z, Chen J, Hu X, Yang S, Xuan Z, Lu X Am J Cancer Res. 2020; 10(10):3127-3137.

PMID: 33163261 PMC: 7642659.

Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells.

Alnuqaydan A, Rah B, Almutary A, Chauhan S Am J Cancer Res. 2020; 10(3):799-815.

PMID: 32266092 PMC: 7136917.

Novel Thienopyrimidine Derivative, RP-010, Induces β-Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells.

Amawi H, Hussein N, Boddu S, Karthikeyan C, Williams F, Ashby Jr C Cancers (Basel). 2019; 11(5).

PMID: 31126091 PMC: 6563099. DOI: 10.3390/cancers11050711.

References

Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M . Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. DOI: 10.1056/NEJM198809013190901. View

Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T . beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol. 1999; 155(4):1033-8. PMC: 1867011. DOI: 10.1016/s0002-9440(10)65204-2. View

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

Korinek V, Barker N, Morin P, van Wichen D, de Weger R, Kinzler K . Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997; 275(5307):1784-7. DOI: 10.1126/science.275.5307.1784. View

Morin P, Sparks A, Korinek V, Barker N, Clevers H, Vogelstein B . Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275(5307):1787-90. DOI: 10.1126/science.275.5307.1787. View

Hao X, Tomlinson I, Ilyas M, Palazzo J, Talbot I . Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch. 1997; 431(3):167-72. DOI: 10.1007/s004280050084. View

Novak A, Hsu S, Radeva G, Papkoff J, Montesano R, Roskelley C . Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A. 1998; 95(8):4374-9. PMC: 22496. DOI: 10.1073/pnas.95.8.4374. View

Potempa S, Ridley A . Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell. 1998; 9(8):2185-200. PMC: 25472. DOI: 10.1091/mbc.9.8.2185. View

He T, Sparks A, Rago C, Hermeking H, Zawel L, DA COSTA L . Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-12. DOI: 10.1126/science.281.5382.1509. View

10.

Waltzer L, Bienz M . Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature. 1998; 395(6701):521-5. DOI: 10.1038/26785. View

11.

Cavallo R, Cox R, Moline M, Roose J, Polevoy G, Clevers H . Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature. 1998; 395(6702):604-8. DOI: 10.1038/26982. View

12.

Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P . The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature. 1998; 395(6702):608-12. DOI: 10.1038/26989. View

13.

Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T . Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract. 1998; 194(10):701-4. DOI: 10.1016/s0344-0338(98)80129-5. View

14.

Yin X, Grove L, Datta N, Long M, Prochownik E . C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene. 1999; 18(5):1177-84. DOI: 10.1038/sj.onc.1202410. View

15.

Mann B, Gelos M, Siedow A, Hanski M, Gratchev A, Ilyas M . Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999; 96(4):1603-8. PMC: 15532. DOI: 10.1073/pnas.96.4.1603. View

16.

Wielenga V, Smits R, Korinek V, Smit L, Kielman M, Fodde R . Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999; 154(2):515-23. PMC: 1850011. DOI: 10.1016/S0002-9440(10)65297-2. View

17.

Samowitz W, Powers M, Spirio L, Nollet F, VAN Roy F, Slattery M . Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999; 59(7):1442-4. View

18.

Tetsu O, McCormick F . Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398(6726):422-6. DOI: 10.1038/18884. View

19.

Hugh T, Dillon S, Taylor B, Pignatelli M, Poston G, Kinsella A . Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer. 1999; 80(7):1046-51. PMC: 2363041. DOI: 10.1038/sj.bjc.6690461. View

20.

Crawford H, Fingleton B, Goss K, Rubinfeld B, Polakis P, Matrisian L . The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999; 18(18):2883-91. DOI: 10.1038/sj.onc.1202627. View